{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:47:07Z","timestamp":1784814427538,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["23YOUN21"],"award-info":[{"award-number":["23YOUN21"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT9425-24-1-0589"],"award-info":[{"award-number":["HT9425-24-1-0589"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["24YOUN22"],"award-info":[{"award-number":["24YOUN22"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["P50 CA 180995"],"award-info":[{"award-number":["P50 CA 180995"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.euo.2025.04.022","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T15:29:36Z","timestamp":1746890976000},"page":"1050-1058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence of Potential Candidates for Targeted Therapies According to Treatment-related Transcriptomic Signatures Among 140 548 Patients with Nonmetastatic Prostate Cancer"],"prefix":"10.1016","volume":"8","author":[{"given":"Nicole","family":"Handa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric V.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Proudfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam B.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridwan","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alshalalfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Hakansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elai","family":"Davicioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip G.","family":"Febbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiten D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"VanderWeele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.04.022_b0005","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2025.04.022_b0010","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2025.04.022_b0015","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2025.04.022_b0020","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2025.04.022_b0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.04.022_b0030","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.04.022_b0035","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/jamaoncol.2021.3987","article-title":"Prognosis associated with luminal and basal subtypes of metastatic prostate cancer","volume":"7","author":"Aggarwal","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2025.04.022_b0040","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","article-title":"Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy","volume":"3","author":"Zhao","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2025.04.022_b0045","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/cncr.34790","article-title":"A novel prostate cancer subtyping classifier based on luminal and basal phenotypes","volume":"129","author":"Weiner","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2025.04.022_b0050","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity \u2014 United States, 2001\u20132017","volume":"69","author":"Siegel","year":"2020","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.euo.2025.04.022_b0055","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamaoncol.2022.1641","article-title":"Enzalutamide monotherapy vs active surveillance in patients with low-risk or intermediate-risk localized prostate cancer: the ENACT randomized clinical trial","volume":"8","author":"Shore","year":"2022","journal-title":"JAMA Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.euo.2025.04.022_b0060","article-title":"1385P Transcriptome-based prognostic and predictive biomarker analysis of ENACT: a randomized controlled trial of enzalutamide (ENZA) in men undergoing active surveillance (AS)","volume":"33","author":"Ross","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.04.022_b0065","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1158\/1078-0432.CCR-19-1587","article-title":"Transcriptomic heterogeneity of androgen receptor activity defines a de novo low AR-active subclass in treatment na\u00efve primary prostate cancer","volume":"25","author":"Spratt","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.04.022_b0070","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147878","article-title":"Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer","volume":"131","author":"Liu","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.euo.2025.04.022_b0075","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41391-021-00416-2","article-title":"A transcriptomic model for homologous recombination deficiency in prostate cancer","volume":"25","author":"Weiner","year":"2022","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euo.2025.04.022_b0080","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41467-017-00147-w","article-title":"Evasion of immunosurveillance by genomic alterations of PPAR\u03b3\/RXR\u03b1 in bladder cancer","volume":"8","author":"Korpal","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2025.04.022_b0085","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-19-0404","article-title":"Novel RB1-loss transcriptomic signature is associated with poor clinical outcomes across cancer types","volume":"25","author":"Chen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.04.022_b0090","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.euo.2020.07.005","article-title":"When and how to use PARP inhibitors in prostate cancer: a systematic review of the literature with an update on on-going trials","volume":"3","author":"Antonarakis","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.euo.2025.04.022_b0095","article-title":"1358O Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): an ancillary study of the STAMPEDE AAP trial","volume":"33","author":"Parry","year":"2022","journal-title":"Ann Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.euo.2025.04.022_b0100","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1200\/JCO.2020.38.15_suppl.5535","article-title":"Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA) or placebo (PBO) to androgen deprivation therapy (ADT) in TITAN","volume":"38","author":"Feng","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.022_b0105","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.04.022_b0110","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41391-022-00496-8","article-title":"NEAR trial: a single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer","volume":"25","author":"Lee","year":"2022","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euo.2025.04.022_b0115","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1158\/1078-0432.CCR-16-1357","article-title":"Neoadjuvant enzalutamide prior to prostatectomy","volume":"23","author":"Montgomery","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.04.022_b0120","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41585-021-00514-9","article-title":"Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer","volume":"18","author":"Devos","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2025.04.022_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01061-x","article-title":"Prostate cancer and PARP inhibitors: progress and challenges","volume":"14","author":"Teyssonneau","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.euo.2025.04.022_b0130","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1200\/JCO.2018.36.15_suppl.5062","article-title":"Prevalence of homologous recombination deficiency (HRD) mutations in localized prostate cancer according to Gleason grade: implications for neoadjuvant clinical trial design","volume":"36","author":"Handy","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.022_b0135","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","article-title":"A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer","volume":"80","author":"Sadaghiani","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.022_b0140","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.04.022_b0145","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.04.022_b0150","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2967\/jnumed.120.257238","article-title":"Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer","volume":"62","author":"Farolfi","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euo.2025.04.022_b0155","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1158\/1055-9965.EPI-13-0668","article-title":"Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer","volume":"22","author":"Kasperzyk","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.euo.2025.04.022_b0160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.euo.2022.09.002","article-title":"Neoadjuvant 177Lu-PSMA-I&T radionuclide treatment in patients with high-risk prostate cancer before radical prostatectomy: a single-arm phase 1 trial","volume":"6","author":"Golan","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.04.022_b0165","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.urology.2020.06.025","article-title":"Predictors of prostate-specific membrane antigen (PSMA\/FOLH1) expression in a genomic database","volume":"144","author":"Bahler","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.04.022_b0170","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.3390\/ijms22147431","article-title":"Enzalutamide enhances PSMA expression of PSMA-low prostate cancer","volume":"22","author":"Staniszewska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euo.2025.04.022_b0175","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.eururo.2024.09.005","article-title":"Molecular hallmarks of prostate-specific membrane antigen in treatment-na\u00efve prostate cancer","volume":"86","author":"Weiner","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.022_b0180","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.3390\/cancers13153737","article-title":"Targeting RB1 loss in cancers","volume":"13","author":"Linn","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2025.04.022_b0185","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.eururo.2020.11.038","article-title":"Novel transcriptomic interactions between immune content and genomic classifier predict lethal outcomes in high-grade prostate cancer","volume":"81","author":"Yamoah","year":"2022","journal-title":"Eur Urol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2025.04.022_b0190","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1200\/JCO.2022.40.6_suppl.156","article-title":"Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC)","volume":"40","author":"Grivas","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.022_b0195","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.trecan.2019.03.005","article-title":"Cell cycle and beyond: exploiting new RB1 controlled mechanisms for cancer therapy","volume":"5","author":"Knudsen","year":"2019","journal-title":"Trends Cancer"},{"issue":"5 Suppl","key":"10.1016\/j.euo.2025.04.022_b0200","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.2025.43.5_suppl.202","article-title":"Assessment of PARP1 mRNA expression as prognostic of aggressive pathology and adverse outcomes, and as predictor of response to PARP inhibition in castration-sensitive prostate cancer","volume":"43","author":"Antonarakis","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:25:59Z","timestamp":1758079559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2588931125001191"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.022","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of Potential Candidates for Targeted Therapies According to Treatment-related Transcriptomic Signatures Among 140 548 Patients with Nonmetastatic Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}